MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
Cellerant Therapeutics
Parents
*Architects: Blood Processing, Blood Pumps, Diagnostics, Hemorrhage, Bleeding, Hemostatis, Transfusion, Intravenous (IV) Management
*Contractors & Awardees: BARDA
*Industry: California
*Industry: California (Biomedical)
Industry: Silicon Valley, California
Children
Amount: $1M Round: Venture Capital Past Investor(s) Biomedical Advanced Research and Development Authority, MPM Capital, BD Ventures, Allen & Company, Sagamore BioVentures, Eminent Venture Capital, Camelot Ventures, Cheng Xin Technology Development
Cellerant is developing a cell-based medicine (Myeloid Progenitors / CLT-008) as a treatment for chemotherapy- and radiation-induced neutropenia as well as for Acute Radiation Syndrome.
Cellerant Therapeutics is a biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system.
Industry: Biotechnology Sub-Industry: N/A
San Carlos, California